nodes	percent_of_prediction	percent_of_DWPC	metapath
Naproxen—AKR1C3—uterine cancer	0.401	1	CbGaD
Naproxen—AKR1C3—Medroxyprogesterone Acetate—uterine cancer	0.242	0.557	CbGbCtD
Naproxen—AKR1C3—Doxorubicin—uterine cancer	0.0489	0.113	CbGbCtD
Naproxen—UGT2B7—Epirubicin—uterine cancer	0.0287	0.0662	CbGbCtD
Naproxen—UGT1A1—Etoposide—uterine cancer	0.0193	0.0446	CbGbCtD
Naproxen—CYP2C8—Medroxyprogesterone Acetate—uterine cancer	0.0191	0.044	CbGbCtD
Naproxen—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.0133	0.0307	CbGbCtD
Naproxen—CYP2C8—Progesterone—uterine cancer	0.0127	0.0292	CbGbCtD
Naproxen—PTGS2—Etoposide—uterine cancer	0.0116	0.0268	CbGbCtD
Naproxen—PTGS1—Etoposide—uterine cancer	0.00981	0.0226	CbGbCtD
Naproxen—CYP1A2—Progesterone—uterine cancer	0.00979	0.0226	CbGbCtD
Naproxen—CYP2C9—Progesterone—uterine cancer	0.00883	0.0203	CbGbCtD
Naproxen—CYP2C8—Etoposide—uterine cancer	0.00566	0.0131	CbGbCtD
Naproxen—CYP1A2—Etoposide—uterine cancer	0.00438	0.0101	CbGbCtD
Naproxen—AKR1C3—Podofilox—Etoposide—uterine cancer	0.00171	1	CbGdCrCtD
Naproxen—PTGS1—oviduct—uterine cancer	0.0011	0.0593	CbGeAlD
Naproxen—AKR1C3—myometrium—uterine cancer	0.00099	0.0537	CbGeAlD
Naproxen—Indomethacin—AKR1C3—uterine cancer	0.00079	0.391	CrCbGaD
Naproxen—UGT2B7—renal system—uterine cancer	0.000782	0.0424	CbGeAlD
Naproxen—AKR1C3—uterine cervix—uterine cancer	0.000771	0.0418	CbGeAlD
Naproxen—AKR1C3—smooth muscle tissue—uterine cancer	0.000749	0.0406	CbGeAlD
Naproxen—AKR1C3—decidua—uterine cancer	0.000734	0.0398	CbGeAlD
Naproxen—PTGS1—artery—uterine cancer	0.000725	0.0393	CbGeAlD
Naproxen—AKR1C3—endometrium—uterine cancer	0.000697	0.0378	CbGeAlD
Naproxen—PTGS2—artery—uterine cancer	0.000693	0.0376	CbGeAlD
Naproxen—AKR1C3—mammalian vulva—uterine cancer	0.000674	0.0365	CbGeAlD
Naproxen—UGT1A1—renal system—uterine cancer	0.000665	0.036	CbGeAlD
Naproxen—AKR1C3—uterus—uterine cancer	0.000642	0.0348	CbGeAlD
Naproxen—UGT2B7—female reproductive system—uterine cancer	0.000626	0.0339	CbGeAlD
Naproxen—AKR1C3—female gonad—uterine cancer	0.000525	0.0285	CbGeAlD
Naproxen—AKR1C3—vagina—uterine cancer	0.000522	0.0283	CbGeAlD
Naproxen—Indomethacin—CXCL8—uterine cancer	0.000475	0.235	CrCbGaD
Naproxen—SLCO1A2—renal system—uterine cancer	0.00045	0.0244	CbGeAlD
Naproxen—Ketoprofen—CXCL8—uterine cancer	0.00038	0.188	CrCbGaD
Naproxen—Ibuprofen—CXCL8—uterine cancer	0.000374	0.185	CrCbGaD
Naproxen—AKR1C3—lymph node—uterine cancer	0.000338	0.0183	CbGeAlD
Naproxen—PTGS2—myometrium—uterine cancer	0.000335	0.0181	CbGeAlD
Naproxen—CYP2C8—renal system—uterine cancer	0.000315	0.017	CbGeAlD
Naproxen—CYP2C8—endometrium—uterine cancer	0.000304	0.0165	CbGeAlD
Naproxen—CYP1A2—renal system—uterine cancer	0.000294	0.016	CbGeAlD
Naproxen—PTGS1—epithelium—uterine cancer	0.000275	0.0149	CbGeAlD
Naproxen—PTGS1—uterine cervix—uterine cancer	0.000273	0.0148	CbGeAlD
Naproxen—PTGS1—smooth muscle tissue—uterine cancer	0.000265	0.0144	CbGeAlD
Naproxen—PTGS2—epithelium—uterine cancer	0.000263	0.0142	CbGeAlD
Naproxen—PTGS2—uterine cervix—uterine cancer	0.000261	0.0141	CbGeAlD
Naproxen—PTGS1—renal system—uterine cancer	0.000255	0.0138	CbGeAlD
Naproxen—PTGS2—smooth muscle tissue—uterine cancer	0.000253	0.0137	CbGeAlD
Naproxen—CYP2C8—female reproductive system—uterine cancer	0.000252	0.0137	CbGeAlD
Naproxen—PTGS1—endometrium—uterine cancer	0.000247	0.0134	CbGeAlD
Naproxen—PTGS2—renal system—uterine cancer	0.000244	0.0132	CbGeAlD
Naproxen—PTGS1—mammalian vulva—uterine cancer	0.000239	0.0129	CbGeAlD
Naproxen—PTGS2—endometrium—uterine cancer	0.000236	0.0128	CbGeAlD
Naproxen—CYP2C8—vagina—uterine cancer	0.000228	0.0123	CbGeAlD
Naproxen—PTGS1—uterus—uterine cancer	0.000227	0.0123	CbGeAlD
Naproxen—CYP2C9—female reproductive system—uterine cancer	0.000224	0.0121	CbGeAlD
Naproxen—PTGS2—uterus—uterine cancer	0.000217	0.0118	CbGeAlD
Naproxen—ALB—lymph node—uterine cancer	0.00021	0.0114	CbGeAlD
Naproxen—PTGS1—female reproductive system—uterine cancer	0.000204	0.0111	CbGeAlD
Naproxen—PTGS2—female reproductive system—uterine cancer	0.000195	0.0106	CbGeAlD
Naproxen—PTGS1—female gonad—uterine cancer	0.000186	0.0101	CbGeAlD
Naproxen—PTGS1—vagina—uterine cancer	0.000185	0.01	CbGeAlD
Naproxen—PTGS2—female gonad—uterine cancer	0.000178	0.00963	CbGeAlD
Naproxen—PTGS2—vagina—uterine cancer	0.000177	0.00957	CbGeAlD
Naproxen—PTGS1—lymph node—uterine cancer	0.00012	0.00648	CbGeAlD
Naproxen—PTGS2—lymph node—uterine cancer	0.000114	0.00619	CbGeAlD
Naproxen—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	5.15e-05	0.000452	CcSEcCtD
Naproxen—Bronchitis—Epirubicin—uterine cancer	5.14e-05	0.000451	CcSEcCtD
Naproxen—Diarrhoea—Dactinomycin—uterine cancer	5.12e-05	0.00045	CcSEcCtD
Naproxen—Pancytopenia—Epirubicin—uterine cancer	5.07e-05	0.000445	CcSEcCtD
Naproxen—Hypotension—Etoposide—uterine cancer	5.06e-05	0.000445	CcSEcCtD
Naproxen—Gastritis—Doxorubicin—uterine cancer	5.06e-05	0.000444	CcSEcCtD
Naproxen—Muscular weakness—Doxorubicin—uterine cancer	5.04e-05	0.000443	CcSEcCtD
Naproxen—Dysuria—Epirubicin—uterine cancer	4.99e-05	0.000439	CcSEcCtD
Naproxen—Abdominal distension—Doxorubicin—uterine cancer	4.98e-05	0.000437	CcSEcCtD
Naproxen—Dysphagia—Doxorubicin—uterine cancer	4.94e-05	0.000434	CcSEcCtD
Naproxen—Asthma—Doxorubicin—uterine cancer	4.94e-05	0.000434	CcSEcCtD
Naproxen—Influenza—Doxorubicin—uterine cancer	4.94e-05	0.000434	CcSEcCtD
Naproxen—Pollakiuria—Epirubicin—uterine cancer	4.93e-05	0.000433	CcSEcCtD
Naproxen—Eosinophilia—Doxorubicin—uterine cancer	4.89e-05	0.00043	CcSEcCtD
Naproxen—Photosensitivity reaction—Epirubicin—uterine cancer	4.88e-05	0.000428	CcSEcCtD
Naproxen—Paraesthesia—Etoposide—uterine cancer	4.87e-05	0.000427	CcSEcCtD
Naproxen—Pancreatitis—Doxorubicin—uterine cancer	4.85e-05	0.000425	CcSEcCtD
Naproxen—Weight decreased—Epirubicin—uterine cancer	4.83e-05	0.000424	CcSEcCtD
Naproxen—Dyspnoea—Etoposide—uterine cancer	4.83e-05	0.000424	CcSEcCtD
Naproxen—Hyperglycaemia—Epirubicin—uterine cancer	4.82e-05	0.000423	CcSEcCtD
Naproxen—Somnolence—Etoposide—uterine cancer	4.82e-05	0.000423	CcSEcCtD
Naproxen—Angina pectoris—Doxorubicin—uterine cancer	4.81e-05	0.000423	CcSEcCtD
Naproxen—Pneumonia—Epirubicin—uterine cancer	4.79e-05	0.000421	CcSEcCtD
Naproxen—Drowsiness—Epirubicin—uterine cancer	4.76e-05	0.000418	CcSEcCtD
Naproxen—Vomiting—Dactinomycin—uterine cancer	4.76e-05	0.000418	CcSEcCtD
Naproxen—Bronchitis—Doxorubicin—uterine cancer	4.75e-05	0.000417	CcSEcCtD
Naproxen—Stevens-Johnson syndrome—Epirubicin—uterine cancer	4.72e-05	0.000415	CcSEcCtD
Naproxen—Rash—Dactinomycin—uterine cancer	4.72e-05	0.000415	CcSEcCtD
Naproxen—Decreased appetite—Etoposide—uterine cancer	4.71e-05	0.000414	CcSEcCtD
Naproxen—Pancytopenia—Doxorubicin—uterine cancer	4.69e-05	0.000412	CcSEcCtD
Naproxen—Renal failure—Epirubicin—uterine cancer	4.68e-05	0.000411	CcSEcCtD
Naproxen—Gastrointestinal disorder—Etoposide—uterine cancer	4.68e-05	0.000411	CcSEcCtD
Naproxen—Fatigue—Etoposide—uterine cancer	4.67e-05	0.00041	CcSEcCtD
Naproxen—Neuropathy peripheral—Epirubicin—uterine cancer	4.67e-05	0.00041	CcSEcCtD
Naproxen—Stomatitis—Epirubicin—uterine cancer	4.64e-05	0.000408	CcSEcCtD
Naproxen—Jaundice—Epirubicin—uterine cancer	4.64e-05	0.000408	CcSEcCtD
Naproxen—Constipation—Etoposide—uterine cancer	4.63e-05	0.000407	CcSEcCtD
Naproxen—Pain—Etoposide—uterine cancer	4.63e-05	0.000407	CcSEcCtD
Naproxen—Urinary tract infection—Epirubicin—uterine cancer	4.63e-05	0.000406	CcSEcCtD
Naproxen—Conjunctivitis—Epirubicin—uterine cancer	4.63e-05	0.000406	CcSEcCtD
Naproxen—Dysuria—Doxorubicin—uterine cancer	4.62e-05	0.000406	CcSEcCtD
Naproxen—Sweating—Epirubicin—uterine cancer	4.57e-05	0.000401	CcSEcCtD
Naproxen—Pollakiuria—Doxorubicin—uterine cancer	4.57e-05	0.000401	CcSEcCtD
Naproxen—Haematuria—Epirubicin—uterine cancer	4.54e-05	0.000399	CcSEcCtD
Naproxen—Photosensitivity reaction—Doxorubicin—uterine cancer	4.51e-05	0.000396	CcSEcCtD
Naproxen—Hepatobiliary disease—Epirubicin—uterine cancer	4.5e-05	0.000396	CcSEcCtD
Naproxen—Epistaxis—Epirubicin—uterine cancer	4.49e-05	0.000394	CcSEcCtD
Naproxen—Weight decreased—Doxorubicin—uterine cancer	4.47e-05	0.000393	CcSEcCtD
Naproxen—Sinusitis—Epirubicin—uterine cancer	4.47e-05	0.000392	CcSEcCtD
Naproxen—Feeling abnormal—Etoposide—uterine cancer	4.46e-05	0.000392	CcSEcCtD
Naproxen—Hyperglycaemia—Doxorubicin—uterine cancer	4.46e-05	0.000391	CcSEcCtD
Naproxen—Nausea—Dactinomycin—uterine cancer	4.45e-05	0.000391	CcSEcCtD
Naproxen—Agranulocytosis—Epirubicin—uterine cancer	4.44e-05	0.00039	CcSEcCtD
Naproxen—Pneumonia—Doxorubicin—uterine cancer	4.43e-05	0.000389	CcSEcCtD
Naproxen—Gastrointestinal pain—Etoposide—uterine cancer	4.43e-05	0.000389	CcSEcCtD
Naproxen—Drowsiness—Doxorubicin—uterine cancer	4.41e-05	0.000387	CcSEcCtD
Naproxen—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	4.37e-05	0.000384	CcSEcCtD
Naproxen—Renal failure—Doxorubicin—uterine cancer	4.33e-05	0.00038	CcSEcCtD
Naproxen—Neuropathy peripheral—Doxorubicin—uterine cancer	4.32e-05	0.000379	CcSEcCtD
Naproxen—Urticaria—Etoposide—uterine cancer	4.3e-05	0.000378	CcSEcCtD
Naproxen—Haemoglobin—Epirubicin—uterine cancer	4.3e-05	0.000377	CcSEcCtD
Naproxen—Jaundice—Doxorubicin—uterine cancer	4.29e-05	0.000377	CcSEcCtD
Naproxen—Stomatitis—Doxorubicin—uterine cancer	4.29e-05	0.000377	CcSEcCtD
Naproxen—Rhinitis—Epirubicin—uterine cancer	4.29e-05	0.000376	CcSEcCtD
Naproxen—Abdominal pain—Etoposide—uterine cancer	4.28e-05	0.000376	CcSEcCtD
Naproxen—Body temperature increased—Etoposide—uterine cancer	4.28e-05	0.000376	CcSEcCtD
Naproxen—Urinary tract infection—Doxorubicin—uterine cancer	4.28e-05	0.000376	CcSEcCtD
Naproxen—Conjunctivitis—Doxorubicin—uterine cancer	4.28e-05	0.000376	CcSEcCtD
Naproxen—Haemorrhage—Epirubicin—uterine cancer	4.28e-05	0.000375	CcSEcCtD
Naproxen—Hepatitis—Epirubicin—uterine cancer	4.28e-05	0.000375	CcSEcCtD
Naproxen—Pharyngitis—Epirubicin—uterine cancer	4.24e-05	0.000373	CcSEcCtD
Naproxen—Sweating—Doxorubicin—uterine cancer	4.22e-05	0.000371	CcSEcCtD
Naproxen—Urinary tract disorder—Epirubicin—uterine cancer	4.22e-05	0.000371	CcSEcCtD
Naproxen—Oedema peripheral—Epirubicin—uterine cancer	4.21e-05	0.00037	CcSEcCtD
Naproxen—Haematuria—Doxorubicin—uterine cancer	4.2e-05	0.000369	CcSEcCtD
Naproxen—Connective tissue disorder—Epirubicin—uterine cancer	4.2e-05	0.000369	CcSEcCtD
Naproxen—Urethral disorder—Epirubicin—uterine cancer	4.19e-05	0.000368	CcSEcCtD
Naproxen—Hepatobiliary disease—Doxorubicin—uterine cancer	4.17e-05	0.000366	CcSEcCtD
Naproxen—Epistaxis—Doxorubicin—uterine cancer	4.16e-05	0.000365	CcSEcCtD
Naproxen—Sinusitis—Doxorubicin—uterine cancer	4.13e-05	0.000363	CcSEcCtD
Naproxen—Visual impairment—Epirubicin—uterine cancer	4.12e-05	0.000362	CcSEcCtD
Naproxen—Agranulocytosis—Doxorubicin—uterine cancer	4.11e-05	0.000361	CcSEcCtD
Naproxen—Erythema multiforme—Epirubicin—uterine cancer	4.04e-05	0.000355	CcSEcCtD
Naproxen—Eye disorder—Epirubicin—uterine cancer	4e-05	0.000351	CcSEcCtD
Naproxen—Hypersensitivity—Etoposide—uterine cancer	3.99e-05	0.000351	CcSEcCtD
Naproxen—Tinnitus—Epirubicin—uterine cancer	3.99e-05	0.00035	CcSEcCtD
Naproxen—Haemoglobin—Doxorubicin—uterine cancer	3.98e-05	0.000349	CcSEcCtD
Naproxen—Cardiac disorder—Epirubicin—uterine cancer	3.97e-05	0.000348	CcSEcCtD
Naproxen—Rhinitis—Doxorubicin—uterine cancer	3.97e-05	0.000348	CcSEcCtD
Naproxen—Haemorrhage—Doxorubicin—uterine cancer	3.96e-05	0.000347	CcSEcCtD
Naproxen—Hepatitis—Doxorubicin—uterine cancer	3.96e-05	0.000347	CcSEcCtD
Naproxen—Pharyngitis—Doxorubicin—uterine cancer	3.93e-05	0.000345	CcSEcCtD
Naproxen—Urinary tract disorder—Doxorubicin—uterine cancer	3.91e-05	0.000343	CcSEcCtD
Naproxen—Oedema peripheral—Doxorubicin—uterine cancer	3.9e-05	0.000342	CcSEcCtD
Naproxen—Asthenia—Etoposide—uterine cancer	3.89e-05	0.000341	CcSEcCtD
Naproxen—Connective tissue disorder—Doxorubicin—uterine cancer	3.89e-05	0.000341	CcSEcCtD
Naproxen—Angiopathy—Epirubicin—uterine cancer	3.88e-05	0.000341	CcSEcCtD
Naproxen—Urethral disorder—Doxorubicin—uterine cancer	3.88e-05	0.000341	CcSEcCtD
Naproxen—Immune system disorder—Epirubicin—uterine cancer	3.86e-05	0.000339	CcSEcCtD
Naproxen—Mediastinal disorder—Epirubicin—uterine cancer	3.85e-05	0.000338	CcSEcCtD
Naproxen—Chills—Epirubicin—uterine cancer	3.84e-05	0.000337	CcSEcCtD
Naproxen—Pruritus—Etoposide—uterine cancer	3.83e-05	0.000337	CcSEcCtD
Naproxen—Arrhythmia—Epirubicin—uterine cancer	3.82e-05	0.000335	CcSEcCtD
Naproxen—Visual impairment—Doxorubicin—uterine cancer	3.81e-05	0.000335	CcSEcCtD
Naproxen—Alopecia—Epirubicin—uterine cancer	3.78e-05	0.000332	CcSEcCtD
Naproxen—Mental disorder—Epirubicin—uterine cancer	3.75e-05	0.000329	CcSEcCtD
Naproxen—Erythema multiforme—Doxorubicin—uterine cancer	3.74e-05	0.000328	CcSEcCtD
Naproxen—Malnutrition—Epirubicin—uterine cancer	3.72e-05	0.000327	CcSEcCtD
Naproxen—Erythema—Epirubicin—uterine cancer	3.72e-05	0.000327	CcSEcCtD
Naproxen—Diarrhoea—Etoposide—uterine cancer	3.71e-05	0.000326	CcSEcCtD
Naproxen—Eye disorder—Doxorubicin—uterine cancer	3.7e-05	0.000325	CcSEcCtD
Naproxen—Tinnitus—Doxorubicin—uterine cancer	3.69e-05	0.000324	CcSEcCtD
Naproxen—Cardiac disorder—Doxorubicin—uterine cancer	3.67e-05	0.000322	CcSEcCtD
Naproxen—Flatulence—Epirubicin—uterine cancer	3.67e-05	0.000322	CcSEcCtD
Naproxen—Tension—Epirubicin—uterine cancer	3.65e-05	0.000321	CcSEcCtD
Naproxen—Nervousness—Epirubicin—uterine cancer	3.61e-05	0.000317	CcSEcCtD
Naproxen—Angiopathy—Doxorubicin—uterine cancer	3.59e-05	0.000315	CcSEcCtD
Naproxen—Dizziness—Etoposide—uterine cancer	3.58e-05	0.000315	CcSEcCtD
Naproxen—Muscle spasms—Epirubicin—uterine cancer	3.58e-05	0.000314	CcSEcCtD
Naproxen—Immune system disorder—Doxorubicin—uterine cancer	3.57e-05	0.000314	CcSEcCtD
Naproxen—Mediastinal disorder—Doxorubicin—uterine cancer	3.56e-05	0.000313	CcSEcCtD
Naproxen—Chills—Doxorubicin—uterine cancer	3.55e-05	0.000312	CcSEcCtD
Naproxen—Arrhythmia—Doxorubicin—uterine cancer	3.53e-05	0.00031	CcSEcCtD
Naproxen—Vision blurred—Epirubicin—uterine cancer	3.51e-05	0.000308	CcSEcCtD
Naproxen—Alopecia—Doxorubicin—uterine cancer	3.5e-05	0.000307	CcSEcCtD
Naproxen—Mental disorder—Doxorubicin—uterine cancer	3.47e-05	0.000304	CcSEcCtD
Naproxen—Ill-defined disorder—Epirubicin—uterine cancer	3.45e-05	0.000303	CcSEcCtD
Naproxen—Vomiting—Etoposide—uterine cancer	3.45e-05	0.000303	CcSEcCtD
Naproxen—Erythema—Doxorubicin—uterine cancer	3.44e-05	0.000302	CcSEcCtD
Naproxen—Malnutrition—Doxorubicin—uterine cancer	3.44e-05	0.000302	CcSEcCtD
Naproxen—Anaemia—Epirubicin—uterine cancer	3.44e-05	0.000302	CcSEcCtD
Naproxen—Rash—Etoposide—uterine cancer	3.42e-05	0.0003	CcSEcCtD
Naproxen—Dermatitis—Etoposide—uterine cancer	3.41e-05	0.0003	CcSEcCtD
Naproxen—Headache—Etoposide—uterine cancer	3.39e-05	0.000298	CcSEcCtD
Naproxen—Flatulence—Doxorubicin—uterine cancer	3.39e-05	0.000298	CcSEcCtD
Naproxen—Tension—Doxorubicin—uterine cancer	3.38e-05	0.000297	CcSEcCtD
Naproxen—Malaise—Epirubicin—uterine cancer	3.36e-05	0.000295	CcSEcCtD
Naproxen—Nervousness—Doxorubicin—uterine cancer	3.34e-05	0.000294	CcSEcCtD
Naproxen—Vertigo—Epirubicin—uterine cancer	3.34e-05	0.000294	CcSEcCtD
Naproxen—Syncope—Epirubicin—uterine cancer	3.34e-05	0.000293	CcSEcCtD
Naproxen—Leukopenia—Epirubicin—uterine cancer	3.33e-05	0.000293	CcSEcCtD
Naproxen—Muscle spasms—Doxorubicin—uterine cancer	3.31e-05	0.000291	CcSEcCtD
Naproxen—Palpitations—Epirubicin—uterine cancer	3.29e-05	0.000289	CcSEcCtD
Naproxen—Loss of consciousness—Epirubicin—uterine cancer	3.27e-05	0.000287	CcSEcCtD
Naproxen—Cough—Epirubicin—uterine cancer	3.25e-05	0.000285	CcSEcCtD
Naproxen—Vision blurred—Doxorubicin—uterine cancer	3.25e-05	0.000285	CcSEcCtD
Naproxen—Convulsion—Epirubicin—uterine cancer	3.22e-05	0.000283	CcSEcCtD
Naproxen—Nausea—Etoposide—uterine cancer	3.22e-05	0.000283	CcSEcCtD
Naproxen—Hypertension—Epirubicin—uterine cancer	3.21e-05	0.000282	CcSEcCtD
Naproxen—Ill-defined disorder—Doxorubicin—uterine cancer	3.19e-05	0.000281	CcSEcCtD
Naproxen—Anaemia—Doxorubicin—uterine cancer	3.18e-05	0.000279	CcSEcCtD
Naproxen—Chest pain—Epirubicin—uterine cancer	3.17e-05	0.000278	CcSEcCtD
Naproxen—Arthralgia—Epirubicin—uterine cancer	3.17e-05	0.000278	CcSEcCtD
Naproxen—Myalgia—Epirubicin—uterine cancer	3.17e-05	0.000278	CcSEcCtD
Naproxen—Anxiety—Epirubicin—uterine cancer	3.16e-05	0.000277	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	3.15e-05	0.000276	CcSEcCtD
Naproxen—Discomfort—Epirubicin—uterine cancer	3.13e-05	0.000275	CcSEcCtD
Naproxen—Malaise—Doxorubicin—uterine cancer	3.11e-05	0.000273	CcSEcCtD
Naproxen—Dry mouth—Epirubicin—uterine cancer	3.1e-05	0.000272	CcSEcCtD
Naproxen—Vertigo—Doxorubicin—uterine cancer	3.09e-05	0.000272	CcSEcCtD
Naproxen—Syncope—Doxorubicin—uterine cancer	3.09e-05	0.000271	CcSEcCtD
Naproxen—Leukopenia—Doxorubicin—uterine cancer	3.08e-05	0.000271	CcSEcCtD
Naproxen—Confusional state—Epirubicin—uterine cancer	3.06e-05	0.000269	CcSEcCtD
Naproxen—Palpitations—Doxorubicin—uterine cancer	3.04e-05	0.000267	CcSEcCtD
Naproxen—Anaphylactic shock—Epirubicin—uterine cancer	3.04e-05	0.000267	CcSEcCtD
Naproxen—Oedema—Epirubicin—uterine cancer	3.04e-05	0.000267	CcSEcCtD
Naproxen—Loss of consciousness—Doxorubicin—uterine cancer	3.03e-05	0.000266	CcSEcCtD
Naproxen—Infection—Epirubicin—uterine cancer	3.02e-05	0.000265	CcSEcCtD
Naproxen—Cough—Doxorubicin—uterine cancer	3e-05	0.000264	CcSEcCtD
Naproxen—Shock—Epirubicin—uterine cancer	2.99e-05	0.000262	CcSEcCtD
Naproxen—Convulsion—Doxorubicin—uterine cancer	2.98e-05	0.000262	CcSEcCtD
Naproxen—Nervous system disorder—Epirubicin—uterine cancer	2.98e-05	0.000262	CcSEcCtD
Naproxen—Thrombocytopenia—Epirubicin—uterine cancer	2.97e-05	0.000261	CcSEcCtD
Naproxen—Hypertension—Doxorubicin—uterine cancer	2.97e-05	0.000261	CcSEcCtD
Naproxen—Tachycardia—Epirubicin—uterine cancer	2.96e-05	0.00026	CcSEcCtD
Naproxen—Skin disorder—Epirubicin—uterine cancer	2.95e-05	0.000259	CcSEcCtD
Naproxen—Hyperhidrosis—Epirubicin—uterine cancer	2.94e-05	0.000258	CcSEcCtD
Naproxen—Chest pain—Doxorubicin—uterine cancer	2.93e-05	0.000257	CcSEcCtD
Naproxen—Arthralgia—Doxorubicin—uterine cancer	2.93e-05	0.000257	CcSEcCtD
Naproxen—Myalgia—Doxorubicin—uterine cancer	2.93e-05	0.000257	CcSEcCtD
Naproxen—Anxiety—Doxorubicin—uterine cancer	2.92e-05	0.000257	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	2.91e-05	0.000256	CcSEcCtD
Naproxen—Discomfort—Doxorubicin—uterine cancer	2.9e-05	0.000254	CcSEcCtD
Naproxen—Anorexia—Epirubicin—uterine cancer	2.9e-05	0.000254	CcSEcCtD
Naproxen—Dry mouth—Doxorubicin—uterine cancer	2.87e-05	0.000252	CcSEcCtD
Naproxen—Hypotension—Epirubicin—uterine cancer	2.84e-05	0.000249	CcSEcCtD
Naproxen—Confusional state—Doxorubicin—uterine cancer	2.83e-05	0.000249	CcSEcCtD
Naproxen—Anaphylactic shock—Doxorubicin—uterine cancer	2.81e-05	0.000247	CcSEcCtD
Naproxen—Oedema—Doxorubicin—uterine cancer	2.81e-05	0.000247	CcSEcCtD
Naproxen—Infection—Doxorubicin—uterine cancer	2.79e-05	0.000245	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Epirubicin—uterine cancer	2.77e-05	0.000243	CcSEcCtD
Naproxen—Shock—Doxorubicin—uterine cancer	2.76e-05	0.000243	CcSEcCtD
Naproxen—Nervous system disorder—Doxorubicin—uterine cancer	2.76e-05	0.000242	CcSEcCtD
Naproxen—Thrombocytopenia—Doxorubicin—uterine cancer	2.75e-05	0.000242	CcSEcCtD
Naproxen—Insomnia—Epirubicin—uterine cancer	2.75e-05	0.000241	CcSEcCtD
Naproxen—Tachycardia—Doxorubicin—uterine cancer	2.74e-05	0.000241	CcSEcCtD
Naproxen—Skin disorder—Doxorubicin—uterine cancer	2.73e-05	0.00024	CcSEcCtD
Naproxen—Paraesthesia—Epirubicin—uterine cancer	2.73e-05	0.000239	CcSEcCtD
Naproxen—Hyperhidrosis—Doxorubicin—uterine cancer	2.72e-05	0.000239	CcSEcCtD
Naproxen—Dyspnoea—Epirubicin—uterine cancer	2.71e-05	0.000238	CcSEcCtD
Naproxen—Somnolence—Epirubicin—uterine cancer	2.7e-05	0.000237	CcSEcCtD
Naproxen—Anorexia—Doxorubicin—uterine cancer	2.68e-05	0.000235	CcSEcCtD
Naproxen—Dyspepsia—Epirubicin—uterine cancer	2.67e-05	0.000235	CcSEcCtD
Naproxen—Decreased appetite—Epirubicin—uterine cancer	2.64e-05	0.000232	CcSEcCtD
Naproxen—Hypotension—Doxorubicin—uterine cancer	2.63e-05	0.000231	CcSEcCtD
Naproxen—Gastrointestinal disorder—Epirubicin—uterine cancer	2.62e-05	0.00023	CcSEcCtD
Naproxen—Fatigue—Epirubicin—uterine cancer	2.62e-05	0.00023	CcSEcCtD
Naproxen—Constipation—Epirubicin—uterine cancer	2.6e-05	0.000228	CcSEcCtD
Naproxen—Pain—Epirubicin—uterine cancer	2.6e-05	0.000228	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Doxorubicin—uterine cancer	2.56e-05	0.000225	CcSEcCtD
Naproxen—Insomnia—Doxorubicin—uterine cancer	2.54e-05	0.000223	CcSEcCtD
Naproxen—Paraesthesia—Doxorubicin—uterine cancer	2.52e-05	0.000222	CcSEcCtD
Naproxen—Dyspnoea—Doxorubicin—uterine cancer	2.51e-05	0.00022	CcSEcCtD
Naproxen—Feeling abnormal—Epirubicin—uterine cancer	2.5e-05	0.00022	CcSEcCtD
Naproxen—Somnolence—Doxorubicin—uterine cancer	2.5e-05	0.000219	CcSEcCtD
Naproxen—Gastrointestinal pain—Epirubicin—uterine cancer	2.48e-05	0.000218	CcSEcCtD
Naproxen—Dyspepsia—Doxorubicin—uterine cancer	2.47e-05	0.000217	CcSEcCtD
Naproxen—Decreased appetite—Doxorubicin—uterine cancer	2.44e-05	0.000215	CcSEcCtD
Naproxen—Gastrointestinal disorder—Doxorubicin—uterine cancer	2.43e-05	0.000213	CcSEcCtD
Naproxen—Fatigue—Doxorubicin—uterine cancer	2.42e-05	0.000213	CcSEcCtD
Naproxen—Urticaria—Epirubicin—uterine cancer	2.41e-05	0.000212	CcSEcCtD
Naproxen—Pain—Doxorubicin—uterine cancer	2.4e-05	0.000211	CcSEcCtD
Naproxen—Constipation—Doxorubicin—uterine cancer	2.4e-05	0.000211	CcSEcCtD
Naproxen—Abdominal pain—Epirubicin—uterine cancer	2.4e-05	0.000211	CcSEcCtD
Naproxen—Body temperature increased—Epirubicin—uterine cancer	2.4e-05	0.000211	CcSEcCtD
Naproxen—Feeling abnormal—Doxorubicin—uterine cancer	2.32e-05	0.000203	CcSEcCtD
Naproxen—Gastrointestinal pain—Doxorubicin—uterine cancer	2.3e-05	0.000202	CcSEcCtD
Naproxen—Hypersensitivity—Epirubicin—uterine cancer	2.24e-05	0.000197	CcSEcCtD
Naproxen—Urticaria—Doxorubicin—uterine cancer	2.23e-05	0.000196	CcSEcCtD
Naproxen—Abdominal pain—Doxorubicin—uterine cancer	2.22e-05	0.000195	CcSEcCtD
Naproxen—Body temperature increased—Doxorubicin—uterine cancer	2.22e-05	0.000195	CcSEcCtD
Naproxen—Asthenia—Epirubicin—uterine cancer	2.18e-05	0.000191	CcSEcCtD
Naproxen—Pruritus—Epirubicin—uterine cancer	2.15e-05	0.000189	CcSEcCtD
Naproxen—Diarrhoea—Epirubicin—uterine cancer	2.08e-05	0.000182	CcSEcCtD
Naproxen—Hypersensitivity—Doxorubicin—uterine cancer	2.07e-05	0.000182	CcSEcCtD
Naproxen—Asthenia—Doxorubicin—uterine cancer	2.02e-05	0.000177	CcSEcCtD
Naproxen—Dizziness—Epirubicin—uterine cancer	2.01e-05	0.000176	CcSEcCtD
Naproxen—Pruritus—Doxorubicin—uterine cancer	1.99e-05	0.000175	CcSEcCtD
Naproxen—Vomiting—Epirubicin—uterine cancer	1.93e-05	0.00017	CcSEcCtD
Naproxen—Diarrhoea—Doxorubicin—uterine cancer	1.92e-05	0.000169	CcSEcCtD
Naproxen—Rash—Epirubicin—uterine cancer	1.92e-05	0.000168	CcSEcCtD
Naproxen—UGT2B7—Metabolism—DCN—uterine cancer	1.91e-05	0.00066	CbGpPWpGaD
Naproxen—Dermatitis—Epirubicin—uterine cancer	1.91e-05	0.000168	CcSEcCtD
Naproxen—Headache—Epirubicin—uterine cancer	1.9e-05	0.000167	CcSEcCtD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.89e-05	0.000653	CbGpPWpGaD
Naproxen—AKR1C3—Disease—FGFR2—uterine cancer	1.88e-05	0.000649	CbGpPWpGaD
Naproxen—Dizziness—Doxorubicin—uterine cancer	1.86e-05	0.000163	CcSEcCtD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	1.84e-05	0.000634	CbGpPWpGaD
Naproxen—AKR1C3—Disease—MTHFR—uterine cancer	1.81e-05	0.000624	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—uterine cancer	1.81e-05	0.000624	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.81e-05	0.000623	CbGpPWpGaD
Naproxen—Nausea—Epirubicin—uterine cancer	1.8e-05	0.000158	CcSEcCtD
Naproxen—UGT2B7—Metabolism—CYP11A1—uterine cancer	1.8e-05	0.000621	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—AKR1C1—uterine cancer	1.8e-05	0.000619	CbGpPWpGaD
Naproxen—Vomiting—Doxorubicin—uterine cancer	1.79e-05	0.000157	CcSEcCtD
Naproxen—CYP2C8—Metabolism—SRD5A2—uterine cancer	1.78e-05	0.000615	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—NDUFB11—uterine cancer	1.78e-05	0.000615	CbGpPWpGaD
Naproxen—ALB—Hemostasis—IRF1—uterine cancer	1.78e-05	0.000613	CbGpPWpGaD
Naproxen—ALB—Metabolism—NDUFB11—uterine cancer	1.77e-05	0.000611	CbGpPWpGaD
Naproxen—ALB—Metabolism—SRD5A2—uterine cancer	1.77e-05	0.000611	CbGpPWpGaD
Naproxen—Rash—Doxorubicin—uterine cancer	1.77e-05	0.000156	CcSEcCtD
Naproxen—Dermatitis—Doxorubicin—uterine cancer	1.77e-05	0.000155	CcSEcCtD
Naproxen—Headache—Doxorubicin—uterine cancer	1.76e-05	0.000155	CcSEcCtD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.73e-05	0.000597	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	1.73e-05	0.000596	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.72e-05	0.000594	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—RRM2—uterine cancer	1.72e-05	0.000592	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	1.7e-05	0.000587	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—AKR1C3—uterine cancer	1.7e-05	0.000587	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—STK11—uterine cancer	1.69e-05	0.000582	CbGpPWpGaD
Naproxen—PTGS2—Disease—RNF43—uterine cancer	1.69e-05	0.000581	CbGpPWpGaD
Naproxen—Nausea—Doxorubicin—uterine cancer	1.67e-05	0.000147	CcSEcCtD
Naproxen—SLCO1A2—Metabolism—DCN—uterine cancer	1.67e-05	0.000574	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	1.64e-05	0.000564	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	1.63e-05	0.000561	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	1.61e-05	0.000555	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—RRM2—uterine cancer	1.6e-05	0.000552	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—AKR1B1—uterine cancer	1.58e-05	0.000546	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—STAR—uterine cancer	1.58e-05	0.000546	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—SOCS3—uterine cancer	1.58e-05	0.000545	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—TP53—uterine cancer	1.57e-05	0.000542	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—CYP11A1—uterine cancer	1.57e-05	0.000541	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	1.57e-05	0.000541	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—POLD1—uterine cancer	1.57e-05	0.00054	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.57e-05	0.00054	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—DCN—uterine cancer	1.56e-05	0.000536	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—MTHFR—uterine cancer	1.52e-05	0.000523	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CDKN2B—uterine cancer	1.51e-05	0.000522	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	1.5e-05	0.000515	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—AKR1C3—uterine cancer	1.48e-05	0.000511	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	1.48e-05	0.000509	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—IGF1R—uterine cancer	1.47e-05	0.000507	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—CYP11A1—uterine cancer	1.47e-05	0.000505	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—AKR1C1—uterine cancer	1.47e-05	0.000505	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—NDUFB11—uterine cancer	1.45e-05	0.0005	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—SRD5A2—uterine cancer	1.45e-05	0.0005	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	1.42e-05	0.000488	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.41e-05	0.000486	CbGpPWpGaD
Naproxen—PTGS2—Disease—AKR1C1—uterine cancer	1.39e-05	0.000479	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—AKR1C3—uterine cancer	1.38e-05	0.000477	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—SMAD3—uterine cancer	1.38e-05	0.000476	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.34e-05	0.000461	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	1.33e-05	0.000459	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—STK11—uterine cancer	1.33e-05	0.000457	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—CYP19A1—uterine cancer	1.33e-05	0.000457	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—FGFR2—uterine cancer	1.32e-05	0.000454	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—RRM2—uterine cancer	1.31e-05	0.00045	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—STAR—uterine cancer	1.29e-05	0.000444	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—AKR1B1—uterine cancer	1.29e-05	0.000444	CbGpPWpGaD
Naproxen—ALB—Metabolism—STAR—uterine cancer	1.28e-05	0.000442	CbGpPWpGaD
Naproxen—ALB—Metabolism—AKR1B1—uterine cancer	1.28e-05	0.000442	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.27e-05	0.000439	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—DCN—uterine cancer	1.27e-05	0.000437	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.27e-05	0.000437	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—POLD1—uterine cancer	1.24e-05	0.000429	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—SRD5A2—uterine cancer	1.24e-05	0.000428	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—NDUFB11—uterine cancer	1.24e-05	0.000428	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.2e-05	0.000415	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	1.2e-05	0.000415	CbGpPWpGaD
Naproxen—PTGS2—Disease—DCN—uterine cancer	1.2e-05	0.000414	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—CYP11A1—uterine cancer	1.19e-05	0.000412	CbGpPWpGaD
Naproxen—AKR1C3—Disease—ERBB2—uterine cancer	1.18e-05	0.000407	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—AKR1C1—uterine cancer	1.16e-05	0.000401	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—STK11—uterine cancer	1.16e-05	0.000398	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—CYP19A1—uterine cancer	1.16e-05	0.000398	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	1.14e-05	0.000392	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—AKR1C3—uterine cancer	1.13e-05	0.000389	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—ESR1—uterine cancer	1.13e-05	0.000389	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	1.11e-05	0.000381	CbGpPWpGaD
Naproxen—AKR1C3—Disease—CDKN1B—uterine cancer	1.09e-05	0.000377	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.08e-05	0.000374	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—CYP19A1—uterine cancer	1.08e-05	0.000372	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—STK11—uterine cancer	1.08e-05	0.000372	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	1.07e-05	0.000369	CbGpPWpGaD
Naproxen—PTGS2—Disease—AKR1C3—uterine cancer	1.07e-05	0.000369	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—AKR1B1—uterine cancer	1.05e-05	0.000362	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—STAR—uterine cancer	1.05e-05	0.000362	CbGpPWpGaD
Naproxen—PTGS2—Disease—HMGA1—uterine cancer	1.04e-05	0.000359	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.04e-05	0.000358	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—RRM2—uterine cancer	1.04e-05	0.000357	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.03e-05	0.000356	CbGpPWpGaD
Naproxen—AKR1C3—Disease—CTNNB1—uterine cancer	1.03e-05	0.000356	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—VEGFA—uterine cancer	1.02e-05	0.000351	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—POLD1—uterine cancer	1.01e-05	0.000349	CbGpPWpGaD
Naproxen—AKR1C3—Disease—PTEN—uterine cancer	1.01e-05	0.000347	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—DCN—uterine cancer	1.01e-05	0.000347	CbGpPWpGaD
Naproxen—ALB—Metabolism—POLD1—uterine cancer	1.01e-05	0.000347	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—MTHFR—uterine cancer	9.97e-06	0.000344	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CCL2—uterine cancer	9.93e-06	0.000342	CbGpPWpGaD
Naproxen—AKR1C3—Disease—EP300—uterine cancer	9.61e-06	0.000331	CbGpPWpGaD
Naproxen—PTGS2—Disease—FBXW7—uterine cancer	9.53e-06	0.000328	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CYP11A1—uterine cancer	9.48e-06	0.000327	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—AKR1C1—uterine cancer	9.46e-06	0.000326	CbGpPWpGaD
Naproxen—ALB—Metabolism—AKR1C1—uterine cancer	9.41e-06	0.000324	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	9.04e-06	0.000311	CbGpPWpGaD
Naproxen—AKR1C3—Disease—NRAS—uterine cancer	8.99e-06	0.00031	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—STAR—uterine cancer	8.97e-06	0.000309	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—AKR1B1—uterine cancer	8.97e-06	0.000309	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—AKR1C3—uterine cancer	8.95e-06	0.000309	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	8.86e-06	0.000306	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—CYP19A1—uterine cancer	8.79e-06	0.000303	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—STK11—uterine cancer	8.79e-06	0.000303	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—MTHFR—uterine cancer	8.68e-06	0.000299	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PTEN—uterine cancer	8.44e-06	0.000291	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—RRM2—uterine cancer	8.43e-06	0.000291	CbGpPWpGaD
Naproxen—ALB—Metabolism—RRM2—uterine cancer	8.39e-06	0.000289	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—ERBB2—uterine cancer	8.27e-06	0.000285	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	8.25e-06	0.000284	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—POLD1—uterine cancer	8.23e-06	0.000284	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—DCN—uterine cancer	8.19e-06	0.000282	CbGpPWpGaD
Naproxen—ALB—Metabolism—DCN—uterine cancer	8.14e-06	0.000281	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—MTHFR—uterine cancer	8.1e-06	0.000279	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—EP300—uterine cancer	8.05e-06	0.000277	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—PIK3CA—uterine cancer	7.96e-06	0.000275	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	7.87e-06	0.000271	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CXCL8—uterine cancer	7.85e-06	0.00027	CbGpPWpGaD
Naproxen—AKR1C3—Disease—KRAS—uterine cancer	7.74e-06	0.000267	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CYP11A1—uterine cancer	7.71e-06	0.000266	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—AKR1C1—uterine cancer	7.7e-06	0.000265	CbGpPWpGaD
Naproxen—ALB—Metabolism—CYP11A1—uterine cancer	7.67e-06	0.000264	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CDKN1B—uterine cancer	7.66e-06	0.000264	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	7.65e-06	0.000264	CbGpPWpGaD
Naproxen—PTGS2—Disease—CDKN2B—uterine cancer	7.47e-06	0.000257	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—AKR1C3—uterine cancer	7.29e-06	0.000251	CbGpPWpGaD
Naproxen—ALB—Metabolism—AKR1C3—uterine cancer	7.24e-06	0.00025	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CTNNB1—uterine cancer	7.24e-06	0.00025	CbGpPWpGaD
Naproxen—AKR1C3—Disease—PIK3CA—uterine cancer	7.11e-06	0.000245	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PTEN—uterine cancer	7.06e-06	0.000243	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—POLD1—uterine cancer	7.04e-06	0.000243	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CYP19A1—uterine cancer	6.98e-06	0.00024	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—STK11—uterine cancer	6.98e-06	0.00024	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—RRM2—uterine cancer	6.86e-06	0.000237	CbGpPWpGaD
Naproxen—PTGS2—Disease—SMAD3—uterine cancer	6.82e-06	0.000235	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—EP300—uterine cancer	6.73e-06	0.000232	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—DCN—uterine cancer	6.66e-06	0.00023	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—MTHFR—uterine cancer	6.6e-06	0.000228	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—AKR1C1—uterine cancer	6.58e-06	0.000227	CbGpPWpGaD
Naproxen—AKR1C3—Disease—HRAS—uterine cancer	6.58e-06	0.000227	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	6.55e-06	0.000226	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—AKT1—uterine cancer	6.51e-06	0.000224	CbGpPWpGaD
Naproxen—PTGS2—Disease—FGFR2—uterine cancer	6.5e-06	0.000224	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—VEGFA—uterine cancer	6.37e-06	0.00022	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—NRAS—uterine cancer	6.3e-06	0.000217	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CYP11A1—uterine cancer	6.28e-06	0.000216	CbGpPWpGaD
Naproxen—PTGS2—Disease—MTHFR—uterine cancer	6.26e-06	0.000216	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	6.24e-06	0.000215	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PIK3CA—uterine cancer	5.95e-06	0.000205	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—AKR1C3—uterine cancer	5.93e-06	0.000204	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—RRM2—uterine cancer	5.87e-06	0.000202	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	5.82e-06	0.000201	CbGpPWpGaD
Naproxen—AKR1C3—Disease—AKT1—uterine cancer	5.81e-06	0.0002	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—DCN—uterine cancer	5.69e-06	0.000196	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—STK11—uterine cancer	5.68e-06	0.000196	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CYP19A1—uterine cancer	5.68e-06	0.000196	CbGpPWpGaD
Naproxen—ALB—Metabolism—STK11—uterine cancer	5.64e-06	0.000195	CbGpPWpGaD
Naproxen—ALB—Metabolism—CYP19A1—uterine cancer	5.64e-06	0.000195	CbGpPWpGaD
Naproxen—ALB—Hemostasis—EP300—uterine cancer	5.55e-06	0.000191	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PTEN—uterine cancer	5.55e-06	0.000191	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—KRAS—uterine cancer	5.42e-06	0.000187	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CYP11A1—uterine cancer	5.37e-06	0.000185	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	5.33e-06	0.000184	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	5.3e-06	0.000183	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—EP300—uterine cancer	5.29e-06	0.000182	CbGpPWpGaD
Naproxen—ALB—Hemostasis—VEGFA—uterine cancer	5.26e-06	0.000181	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—MTHFR—uterine cancer	5.24e-06	0.000181	CbGpPWpGaD
Naproxen—ALB—Hemostasis—NRAS—uterine cancer	5.19e-06	0.000179	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—EP300—uterine cancer	5.08e-06	0.000175	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—AKR1C3—uterine cancer	5.07e-06	0.000175	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—EP300—uterine cancer	5.05e-06	0.000174	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PIK3CA—uterine cancer	4.98e-06	0.000172	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—AKT1—uterine cancer	4.86e-06	0.000168	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PTEN—uterine cancer	4.83e-06	0.000166	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TP53—uterine cancer	4.82e-06	0.000166	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CYP19A1—uterine cancer	4.62e-06	0.000159	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—STK11—uterine cancer	4.62e-06	0.000159	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4.62e-06	0.000159	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—HRAS—uterine cancer	4.61e-06	0.000159	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—EP300—uterine cancer	4.6e-06	0.000159	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PTEN—uterine cancer	4.51e-06	0.000155	CbGpPWpGaD
Naproxen—ALB—Hemostasis—KRAS—uterine cancer	4.47e-06	0.000154	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	4.34e-06	0.000149	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—EP300—uterine cancer	4.3e-06	0.000148	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—MTHFR—uterine cancer	4.26e-06	0.000147	CbGpPWpGaD
Naproxen—ALB—Metabolism—MTHFR—uterine cancer	4.24e-06	0.000146	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	4.14e-06	0.000143	CbGpPWpGaD
Naproxen—ALB—Hemostasis—PIK3CA—uterine cancer	4.1e-06	0.000141	CbGpPWpGaD
Naproxen—PTGS2—Disease—ERBB2—uterine cancer	4.08e-06	0.000141	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—AKT1—uterine cancer	4.07e-06	0.00014	CbGpPWpGaD
Naproxen—ALB—Hemostasis—TP53—uterine cancer	3.97e-06	0.000137	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—STK11—uterine cancer	3.95e-06	0.000136	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CYP19A1—uterine cancer	3.95e-06	0.000136	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PIK3CA—uterine cancer	3.91e-06	0.000135	CbGpPWpGaD
Naproxen—ALB—Hemostasis—HRAS—uterine cancer	3.8e-06	0.000131	CbGpPWpGaD
Naproxen—PTGS2—Disease—CDKN1B—uterine cancer	3.78e-06	0.00013	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.76e-06	0.00013	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.74e-06	0.000129	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	3.71e-06	0.000128	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PTEN—uterine cancer	3.67e-06	0.000127	CbGpPWpGaD
Naproxen—PTGS2—Disease—CTNNB1—uterine cancer	3.57e-06	0.000123	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	3.53e-06	0.000122	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—EP300—uterine cancer	3.5e-06	0.000121	CbGpPWpGaD
Naproxen—PTGS2—Disease—PTEN—uterine cancer	3.48e-06	0.00012	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—MTHFR—uterine cancer	3.47e-06	0.00012	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PIK3CA—uterine cancer	3.41e-06	0.000117	CbGpPWpGaD
Naproxen—ALB—Hemostasis—AKT1—uterine cancer	3.35e-06	0.000116	CbGpPWpGaD
Naproxen—PTGS2—Disease—EP300—uterine cancer	3.32e-06	0.000114	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—AKT1—uterine cancer	3.2e-06	0.00011	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PIK3CA—uterine cancer	3.18e-06	0.00011	CbGpPWpGaD
Naproxen—PTGS2—Disease—NRAS—uterine cancer	3.11e-06	0.000107	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.06e-06	0.000105	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—MTHFR—uterine cancer	2.97e-06	0.000102	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PTEN—uterine cancer	2.92e-06	0.000101	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—AKT1—uterine cancer	2.78e-06	9.59e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—EP300—uterine cancer	2.78e-06	9.59e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—KRAS—uterine cancer	2.67e-06	9.22e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.61e-06	9.01e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—AKT1—uterine cancer	2.6e-06	8.95e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PIK3CA—uterine cancer	2.59e-06	8.93e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—PIK3CA—uterine cancer	2.46e-06	8.47e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PTEN—uterine cancer	2.37e-06	8.18e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PTEN—uterine cancer	2.36e-06	8.13e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—HRAS—uterine cancer	2.27e-06	7.83e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—EP300—uterine cancer	2.26e-06	7.8e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—EP300—uterine cancer	2.25e-06	7.76e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—AKT1—uterine cancer	2.12e-06	7.3e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PIK3CA—uterine cancer	2.06e-06	7.09e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—AKT1—uterine cancer	2.01e-06	6.92e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PTEN—uterine cancer	1.93e-06	6.66e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—EP300—uterine cancer	1.84e-06	6.35e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—AKT1—uterine cancer	1.68e-06	5.79e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PIK3CA—uterine cancer	1.67e-06	5.77e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PIK3CA—uterine cancer	1.66e-06	5.74e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PTEN—uterine cancer	1.65e-06	5.69e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—EP300—uterine cancer	1.57e-06	5.42e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—AKT1—uterine cancer	1.37e-06	4.71e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PIK3CA—uterine cancer	1.36e-06	4.7e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—AKT1—uterine cancer	1.36e-06	4.69e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PIK3CA—uterine cancer	1.16e-06	4.01e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—AKT1—uterine cancer	1.11e-06	3.84e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—AKT1—uterine cancer	9.51e-07	3.28e-05	CbGpPWpGaD
